Why CannTrust (TSX:TRST) Crashed More Than 20% Yesterday

CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) found itself in some hot water with Health Canada after being non-compliant with some of its regulations.

Tired or stressed businessman sitting on the walkway in panic digital stock market financial background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) investors got more bad news on Monday when they learned that the company’s operations were found non-compliant with Health Canada’s regulations.

In its Pelham, Ontario facility, CannTrust had been growing cannabis in rooms that were not yet licensed and still pending approval. Although they did ultimately receiving licenses in April 2019, it didn’t change the fact that the company was growing in the rooms prior to then.

What’s also troubling is that regulators noted that “inaccurate information” was provided by CannTrust employees. As a result of the infractions, Health Canada is holding 5,200 kilograms of dried cannabis that CannTrust previously harvested from those rooms. The company is also voluntarily holding 7,500 kilograms at its Vaughn location, which also has cannabis produced from those rooms.

What Health Canada is doing now is performing quality checks on the samples that have been held at Pelham, which is expected to take at least two weeks. The problem in the interim is that now those products can’t be shipped to customers and patients and will cause shortages until Health Canada releases them — assuming it does so.

CannTrust’s CEO Peter Aceto affirms that the company has made the necessary changes and that it will learn from its mistakes: “We have made many changes to make this right with Health Canada. We made errors in judgement, but the lessons we have learned here will serve us well moving forward.” Some of the changes noted by the company that it plans to make include more employee training, and reviews of the processes done by external advisors.

The company couldn’t provide an estimate as to the potential impact on its financials given the uncertainty around the current hold and when the products will be released.

Key takeaways for investors

There are two big concerns I see from this, neither of which relate to sales, at least not directly.

The first is that these added quality control measures, while important, will add a lot more cost to the company’s income statement. With losses being a big problem in the industry and CannTrust reporting a significant net loss last quarter, it may make it even less likely that the company is able to get to breakeven anytime soon.

The company will likely overcompensate for the audit failure, and while it’s understandable to help win back the trust of investors, it’s going to come at a price.

The other concern is the trust issue. In the cannabis industry, investors are starting to worry that the growth prospects in Canada may not be as good as advertised, and so having and establishing trust is critical for companies.

With CannTrust misleading regulators on its facilities, it damages that trust, and the stock had already been struggling, losing 37% of its value over the past three months entering Monday’s trading session, which is going to make raising capital even more challenging.

It may take some time for the company to win back the trust of investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »